abs186.txt	objective		to	determine	the	disease-free	survival	(dfs)	and	recurrence	after	thetreatment	of	patients	with	rectal	cancer	open	(open)	or	laparoscopic	(lap)resection	background	this	randomized	clinical	trial	(acosog	[alliance]	z6051)	performedbetween	2008	2013	compared	lap	resection	stage	ii/iii	rectalcancer	within	12	cm	anal	verge	(t1-3	n0-2	m0)	in	who	receivedneoadjuvant	chemoradiotherapy	rectum	mesorectum	were	resected	using	openinstruments	for	dissection	(included	hybrid	hand-assisted	laparoscopic)	orwith	instruments	under	pneumoperitoneum	2-year	dfs	andrecurrence	secondary	endpoints	z6051	methods	not	powered	are	being	assessed	forsuperiority	was	determined	at	3	6	9	every	monthsthereafter	carcinoembryonic	antigen	physical	examination	computedtomography	colonoscopy	all	486	(243)	oropen	462	eligible	analysis	(lap	=	240	222)	medianfollow-up	is	47	months	results	79	5%	(95%	confidence	interval	[ci]	74	4-84	9)and	83	2%	ci	78	3-88	3)	local	regional	4	6%	and4	distant	14	16	7%	survivalwas	impacted	by	unsuccessful	(hazard	ratio	[hr]	1	87	95%	ci1	21-2	91)	composite	incomplete	specimen	(hr	65	0	85-3	18)	positive	circumferential	margins	2	31	40-3	79)	positivedistal	margin	53	30-3	77)	conclusion	assisted	found	besignificantly	different	based	on	outcomesof
